CA
ATRS

CapWealth Advisors’s Antares Pharma, Inc. ATRS Stock Holding History

CapWealth Advisors’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-1,800
Closed -$7K – 422
2013
Q3 		$7K Buy
+1,800
New +$7.86K ﹤0.01% 344

Other funds holding ATRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

CapWealth Advisors's ATRS Position: Q4 2013 in Review

CapWealth Advisors sold out of Antares Pharma, Inc. (ATRS) in Q4 2013, closing a stake of 1,800 shares — an estimated $7K sold.

CapWealth Advisors first reported a position in ATRS in Q3 2013 and held it in 1 quarter. The position peaked at $7K in Q3 2013. 89 funds tracked by Wall St. Rank hold ATRS as of Q4 2013.

  • CapWealth Advisors reported no remaining Antares Pharma, Inc. position as of Q4 2013 after selling out during the quarter.
  • CapWealth Advisors sold 1,800 Antares Pharma, Inc. shares in Q4 2013, an estimated $7K.
  • CapWealth Advisors first reported a position in Antares Pharma, Inc. in Q3 2013 and held it in 1 quarter.
  • CapWealth Advisors's Antares Pharma, Inc. position peaked at $7K in Q3 2013.
  • 89 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2013.

Based on CapWealth Advisors's 13F filing for Q4 2013, filed 13 Feb 2014.